The administration of chemotherapy at reduced doses given at regular, frequent time
intervals, termed 'metronomic'chemotherapy, presents an alternative to standard maximal …

Metronomic chemotherapy, continuous and dose‐dense administration of chemotherapeutic
drugs with lowered doses, is being evaluated for substituting, augmenting, or appending …

Toxic effects and chemoresistance are major hurdles in chemotherapy and to avoid these
problems caused by traditional chemotherapeutic regimens, a new modality of drug …

Tumor dormancy is the ability of cancer cells to survive in a non-proliferating state. This
condition can depend on three main mechanisms: cell cycle arrest (quiescence or cell …

Metronomic chemotherapy (MC) refers to the close administration of a chemotherapeutic
drug for a long time with no extended drug-free breaks. It was developed to overcome drug …

Despite evidence of cancer immune-surveillance, which plays a key role in tumor rejection,
cancer cells can escape immune recognition through different mechanisms. Thus, evasion …

Metronomic chemotherapy (mCT), a frequent administration of low-dose chemotherapy,
allows prolonged treatment duration and minimizes the toxicity of standard-dose …

Cyclophosphamide and ifosfamide are major alkylating agents but their therapeutics uses
are limiting by the toxicity due to several toxicities. Indeed conventional chemotherapies are …

Background: Although there are reports that metronomic cyclophosphamide (CTX) can be
immune stimulating, the impact of its combination with anti-CTLA-4 immunotherapy for the …

Therapeutic resistance is amongst the major determinants of cancer mortality. Contrary to
initial expectations, antivascular therapies are equally prone to inherent or acquired …